Fox (NASDAQ:FOX) Bolsa

Fox operates in two segments: cable networks and television. Cable networks primarily includes Fox News, Fox Business, and several pay-TV sports stations. Television primarily includes the Fox broadcast network, 29 owned and operated local television stations, of which 18 are affiliated with the Fox network, and streaming platform Tubi, which is not subscription-based and is completely ad-supported. Fox effectively sold most of its entertainment assets to Disney in 2019, so it no longer creates entertainment content and relies heavily on live news and sports, with nearly all tied to the pay-TV bundle. The Murdoch family controls Fox.

Screenshot,Of,Buying,Male,Stocks,And,Futures,Markets,In,Thailand

Earnings

News

Markets

Trading Ideas

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este lunes: FOX, HE, NRG, DVA y SWX.

5 acciones en el foco este lunes: FOX, HE, NRG, DVA y SWX

Fox Corp

Shapeshift FOX Token - United States Dollar

Fox Factory Holding Corp

FOXO Technologies Inc. Class A Common Stock

FOXO Technologies Inc

FOXO Technologies Inc Warrants (01/08/2027)

Foxx Development Holdings Inc. - Common Stock

Foxx Development Holdings Inc

Simplify Exchange Traded Funds Simplify Currency Strategy ETF

FOXY - United States Dollar

Currently trading at $0.00001630, Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) has marked <a href="https://www.benzinga.com/money/how-to-buy-shiba-inu">a substantial 27.5% gain on the weekly chart</a>. Crypto analyst, CryptoGuru, highlighted that SHIB has broken out cleanly from a descending channel and suggested a potential 68% upward move if the current pullback maintains support at the breakout level.
"Price reclaimed the 21 EMA and is now pulling back slightly" said CryptoGuru.
Don't Miss:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/go/plus-500-crypto-in-content">Trade crypto futures on Plus500 with up to $200 in bonuses</a> — no wallets, just price speculation and free paper trading to practice different strategies.</li>
<li>New to trading crypto? <a href="http://coinbase-consumer.sjv.io/m5ALXy">Get up to $400 in rewards for successfully completing short educational courses and placing your first qualifying trade</a> on Coinbase.</li>
</ul>
Shiba Inu has seen an increase in trading volume, as per the data shared by a news report on U.Today. Although trading volume across the market saw a dip, the SHIB/USDT trading volume on Binance has jumped by 8% in the last 24 hours. This indicates strong adoption of the meme coin.
The daily burn rate for Shiba Inu tokens has skyrocketed by a staggering 6,519%. According to Coinspeaker, more than 28.7 million SHIB tokens were removed from circulation in the last 24 hours.
The increase reverses a previous seven-day period that saw the burn rate drop by more than 80%. Such a burn rate could reduce the supply of SHIB tokens significantly to create scarcity. This may result in price inflation if the demand rises.
The strong performance of Shiba Inu coincides with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) hovering near its all-time highs, which has generally fueled positive momentum across the meme coin sector. Per CoinMarketCap, the BTC price is currently $103,701, which has soared by 7.44% in the past week.
Historically, Bitcoin's bull run has often resulted in a positive rally for memecoins since it is the largest cryptocurrency by market cap, and represents the majority of crypto traders and their sentiments toward the industry. So, Shiba Inu's current price rise could very well sustain, considering the growth and stability BTC has shown.
According to IntoTheBlock, 74% of SHIB tokens are held by large investors (whales), which indicates strong confidence from this segment.
Besides, a substantial 78% of SHIB investors have held their tokens for over a year, reports Watcher.Guru. This hints at long-term conviction within the SHIB community, which is vital for a sustained growth.
As Shiba Inu maintains its breakout from the descending channel, and experiences increased trading volume alongside a significant burn rate spike, SHIB price appears to be capitalizing on the broader market momentum and renewed speculative interest.
However, as a meme coin, SHIB is quite susceptible to the highly volatile and sentiment-driven nature of the market. Investors will need to closely watch volume and support levels to confirm the potential continuation of this bullish trend.
More Opportunities:
<ul class="wp-block-list">
<li>Grow your IRA or 401(k) with Crypto – <a href="https://info.irafinancial.com/lp/irafi-crypto/?utm_source=benzinga.com&amp;utm_medium=affiliate&amp;utm_campaign=y2">unlock the power of alternative investments including a Crypto IRA within your retirement account</a>.</li>
<li>Trade, earn, and grow your crypto portfolio with Crypto.com — <a href="https://www.benzinga.com/go/crypto-com-signup-bonus">plus receive up to $500 worth of rewards in the most popular tokens if you're a new customer</a>.</li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$SHIB

Shiba Inu Price Breaks Out: Can Soaring Burn Rate Sustain the Bullish Momentum?

Global-E Online Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) shares are trading lower after the company <a href="https://www.benzinga.com/pressreleases/25/05/g45402182/global-e-reports-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">reported its first-quarter FY25 results</a>.
Sales grew 30% year over year (Y/Y) to $189.9 million, beating the analyst consensus estimate of $187.87 million. Gross Merchandise Value (GMV) rose 34% Y/Y to $1.24 billion in the quarter.
The company reported&nbsp;$84.0&nbsp;million&nbsp;in service fees and&nbsp;$105.9&nbsp;million&nbsp;in fulfillment services revenue&nbsp;in the quarter.
Non-GAAP gross profit increased&nbsp;to&nbsp;$86.3&nbsp;million&nbsp;(+31%&nbsp;Y/Y), and non-GAAP gross margin expanded 10 basis points Y/Y to&nbsp;45.4%.
Adjusted EBITDA rose to&nbsp;$31.6&nbsp;million&nbsp;from&nbsp;$21.3&nbsp;million&nbsp;a year ago. The company's operating loss narrowed to&nbsp;$19.2 million&nbsp;from&nbsp;$29.3 million.
Loss per share was&nbsp;$0.11,&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beating the consensus loss of&nbsp;$0.13.</a>
Outlook: For the&nbsp;second quarter, Global-e Online projects GMV of&nbsp;$1.387 billion&nbsp;&#8211; $1.427 billion and revenue of&nbsp;$204 million&nbsp;to <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$211 million&nbsp;vs.&nbsp;$209.63 million&nbsp;estimate</a>.
The company reiterated its FY25 guidance&nbsp;for GMV at $6.190 billion &#8211; $6.490 billion and revenue at $917 million &#8211; $967 million vs. the consensus&nbsp;of&nbsp;$931.39 million.
&#8220;We had another quarter of strong results, demonstrating our ability to grow fast even within macroeconomic turbulent times with Q1 results coming in at or above the midpoints across our guidance,&#8221; founder and CEO Amir Schlachet said.  
&#8221;While the market remains volatile with a higher level of uncertainty given the ongoing global duty tariff dynamics, our pipeline is very active and we see increased interest in our services.&#8221;
In a separate release, the company disclosed a new 3-year strategic partnership agreement with Shopify Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NASDAQ">SHOP</a>) which extends the companies&#8217; existing long-term strategic partnership for both their first-party (1P, i.e., Shopify Managed Markets) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45401960/global-e-and-shopify-sign-new-multi-year-strategic-partnership-agreement-extending-relationship" rel="noreferrer noopener">and third-party (3P) solutions</a>.
Investors can gain exposure to the stock via Amplify ETF Trust Amplify BlueStar Israel Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITEQ#NYSE">ITEQ</a>) and First Trust Exchange-Traded Fund VIII FT Raymond James Multicap Growth Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJMG#NYSE">RJMG</a>).
Price Action: At the last check on Wednesday, GLBE shares were trading lower by 14.60% at $36.20 premarket.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/25/04/44672420/pros-global-e-sps-commerce-stand-out-as-tariffs-reshape-software-spending-priorities-analyst" target="_blank" rel="noreferrer noopener">PROS, Global-E, SPS Commerce Stand Out As Tariffs Reshape Software Spending Priorities: Analyst</a></li>
</ul>
Photo: Shutterstock

Equities

Mid Cap

Guidance

Movers

GLBE

ITEQ

RJMG

SHOP

Global-e Q1: Sales Up 30%, GMV Soars 34%, Extends Strategic Partnership With Shopify

Cantor Fitzgerald analyst Rick Bienkowski reiterates Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) with a Overweight and maintains $55 price target.

Price Target

Reiteration

Analyst Ratings

LEGN

Cantor Fitzgerald Reiterates Overweight on Legend Biotech, Maintains $55 Price Target

Mizuho analyst James Lee maintains JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) with a Outperform and lowers the price target from $50 to $48.

Mizuho Maintains Outperform on JD.com, Lowers Price Target to $48

Barclays analyst Michael Leithead maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Equal-Weight and raises the price target from $59 to $62.

Barclays Maintains Equal-Weight on Celanese, Raises Price Target to $62

Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) announced on Wednesday that its board of directors approved a new $6 billion <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45405418/amd-announces-new-6-billion-share-repurchase-authorization" rel="noreferrer noopener">share repurchase program</a>.
The new authorization is in addition to the remaining balance, as of March 29, of approximately $4 billion of its existing share repurchase program, increasing the total current repurchase authority to roughly $10 billion.
The stock is trading higher after the update.
Also Read: <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45384346/amd-launches-epyc-4005-chips-for-small-business-and-cloud" target="_blank" rel="noreferrer noopener">AMD Launches EPYC 4005 Chips For Small Business And Cloud</a>
AMD stock is down close to 7% year-to-date. Uncertainty surrounding U.S. tariff policies took a toll on the entire sector.
The company is engaged in intensifying competition with Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) GPUs.
However, semiconductor stocks got a boost this week after Beijing and Washington <a target="_blank" href="https://www.benzinga.com/government/regulations/25/05/45352452/why-are-nvidia-and-other-chip-stocks-trading-higher-on-monday" rel="noreferrer noopener">temporarily agreed to</a> lower tariffs on each other&#8217;s products. Bloomberg reported on Wednesday, citing unnamed sources familiar with the matter, that the US also looks to rescind the Biden administration&#8217;s artificial intelligence diffusion, which created three broad tiers of access for countries seeking AI chips and would have taken effect May 15. Instead, the US government is drafting its approach and could forge individual deals with countries.
President Trump also announced <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/25/05/45390422/trump-unveils-historic-and-transformative-600-billion-saudi-deal-predicts-markets-will-go-a-lot-higher" rel="noreferrer noopener">multi-billion dollar commercial</a> deals from Saudi Arabia with&nbsp;companies, including Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and AMD.
AMD held $7.31 billion in cash and equivalents as of March 29, 2025.
Last week, AMD reported <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45237261/amd-q1-earnings-revenue-eps-beat-driven-by-expanding-data-center-ai-momentum-chipmaker-expects-strong-growth-in-2025" rel="noreferrer noopener">first-quarter revenue</a> of $7.44 billion, up 36%, topping analyst estimates of $7.13 billion. The chipmaker reported first-quarter adjusted earnings of 96 cents per share, beating analyst estimates of 94 cents per share.
AMD expects second-quarter revenue of approximately $7.4 billion, plus or minus $300 million. Analysts are currently forecasting second-quarter revenue of $7.24 billion.
Price Action: AMD stock traded higher by 7.92% to $121.15 at Wednesday&#8217;s last check.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/05/45379380/can-corning-broadcom-deal-transform-ais-data-center-future" target="_blank" rel="noreferrer noopener">Can Corning-Broadcom Deal Transform AI&#8217;s Data Center Future?</a></li>
</ul>
Image: Shutterstock

Buybacks

Tech

AMZN

NVDA

AMD Stock Pops On $6 Billion Buyback Plan, US Tariff Ease

Bitcoin Price gained 0.67% on Wednesday to reach $103,456.92, which took its weekly gain to 6.91% <a href="https://www.benzinga.com/money/how-to-buy-bitcoin-btc-best-bonuses-august-2024">and monthly to 22.59%</a>. The surge has resulted in Bitcoin gaining reputation as a long-term investment, as investors are now seeing it as more of ‘digital gold' than just a speculative asset.
The U.S. has been seeing rising yields on the 10-year Treasury note after a temporary withdrawal in tariffs between China and the U.S. This boosted the market sentiment and resulted in higher yields, which are currently 4.5%.&nbsp;
Typically, rising yields would signal trouble for non-yielding assets like Bitcoin as investors shift to safe interest-bearing assets. However, this situation is evolving.
Don't Miss:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/go/plus-500-crypto-in-content">Trade crypto futures on Plus500 with up to $200 in bonuses</a> — no wallets, just price speculation and free paper trading to practice different strategies.</li>
<li>New to trading crypto? <a href="http://coinbase-consumer.sjv.io/m5ALXy">Get up to $400 in rewards for successfully completing short educational courses and placing your first qualifying trade on</a> Coinbase. </li>
</ul>
David Lawant, head of research at FalconX, said that Bitcoin is being regarded as &#8220;emerging digital gold.&#8221; He added that despite the increased yields, Bitcoin&#8217;s unique properties are drawing lots of institutional attention. As the currency matures with the passage of time and there&#8217;s more clarity with respect to regulations, institutional investors are thinking about Bitcoin as a long-term repository of value, and not as a risky asset.
The institutional conviction was well on display recently, when a publicly listed firm, Next Technology, reported a $180 million purchase of Bitcoin, a 5,000-BTC addition to its treasury and bringing its holdings to 5,833 BTC.
Meanwhile, notable investors are also discussing the growth potential of Bitcoin. Arthur Hayes recently predicted that eventual U.S. monetary expansion would lead Bitcoin to reach $1 million. Anthony Scaramucci sees the network reaching 1 billion users and a $23 trillion market cap. Tim Draper, who holds 30,000 BTC, reasserted his prediction that Bitcoin would reach $250,000 per coin by year&#8217;s end. He even indicated Bitcoin could replace the U.S. dollar within a decade.
The trend does not end here. On Tuesday, a new investment company, Twenty One Capital, revealed that it has purchased 4,812 BTC valued at $458.7 million, according to BeInCrypto. The firm, founded by Jack Mallers, is supported by industry giants such as Tether, Bitfinex, Cantor Fitzgerald, and SoftBank.
The deal was financed via a PIPE deal and used proceeds of convertible notes. The company describes this as the start of a Bitcoin-native corporate strategy, which they have modeled after the aggressive treasury playbook, initially developed by Michael Saylor&#8217;s Strategy (then MicroStrategy).
As reported by BeInCrypto, Twenty One Capital now has $4.05 billion in BTC, which makes it the third-largest corporate holder of Bitcoin globally, after Strategy and Marathon Digital. Bitcoin advocate, Max Keiser, called this action &#8220;the next wave of Saylorization&#8221; and warned that companies would need to follow similar strategies or they would risk falling behind.
More Opportunities:
<ul class="wp-block-list">
<li>Grow your IRA or 401(k) with Crypto – <a href="https://info.irafinancial.com/lp/irafi-crypto/?utm_source=benzinga.com&amp;utm_medium=affiliate&amp;utm_campaign=y2">unlock the power of alternative investments including a Crypto IRA within your retirement account</a>.</li>
<li>Trade, earn, and grow your crypto portfolio with Crypto.com — <a href="https://www.benzinga.com/go/crypto-com-signup-bonus">plus receive up to $500 worth of rewards in the most popular tokens if you're a new customer</a>.</li>
</ul>
Image: Shutterstock

Bitcoin Considered 'Digital Gold' While It Reaches $103K

Rumors

IPOs

ETOR

Etoro Group IPO Price Indicating $62.50 On 500K Shares; IPO Priced At $52/Share On 11,923,018 Shares

Mizuho analyst Ann Hynes maintains Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Neutral and lowers the price target from $37 to $32.

ACHC

Mizuho Maintains Neutral on Acadia Healthcare Co, Lowers Price Target to $32

A $30 million wipeout in just 60 days—no miscalculation, just tariffs. That's the reality a U.S. entrepreneur recently revealed following President <a href="https://www.benzinga.com/startups/24/09/40969537/trump-familys-crypto-venture-revealed-new-buying-rules-who-can-invest-and-what-it-means-for-early-ad">Donald Trump</a>'s imposition of a 145% tariff on Chinese goods.&nbsp;
On April 17, Mark Cuban shared a <a href="https://x.com/mcuban/status/1911097441580892491?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1911097441580892491%7Ctwgr%5Ed38d2889f79fbcd59e7beabb58b0d9f525b10b38%7Ctwcon%5Es1_&amp;ref_url=https%3A%2F%2Fen.as.com%2Flatest_news%2Fmark-cubans-post-about-an-entrepreneurs-frustration-with-tariffs-what-this-is-going-to-do-to-our-economy-is-frightening-n%2F">post on X</a>. In it, he amplified concerns voiced by an unnamed entrepreneur about the growing damage many businesses say they're now grappling with under Trump's newly unveiled trade plans. The tariffs, which would impact imports from 185 countries, start at 10%, with China facing the steepest rate.
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
<h2 class="wp-block-heading">Businesses Stall, Stock Warnings Grow Louder</h2>
In his post, Cuban quoted the entrepreneur, who said, "$30M in EBITDA wiped out for us in 2 months, a company I spent a decade building decimated in a matter of months. Unbelievable people still don't understand tariffs at this point, and the head in the sand approach to what this is going to do to our economy is frightening. We are in cash preservation mode and have paused all shipments from China at this point."
Trump's trade measures aim to protect American manufacturing by making foreign imports more expensive. But some industries are already responding by freezing operations, cutting costs, and pausing international shipments.
According to <a href="https://www.reuters.com/business/autos-transportation/trumps-tariffs-chinese-parts-cybercab-semi-disrupt-teslas-us-production-plans-2025-04-16/">Reuters</a> on April 15, Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)&nbsp; halted imports of components from China critical to the assembly of its Cybercab and Semi models. Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) redirected a 737 MAX jetliner meant for a Chinese airliner back to the U.S., citing prohibitive cost implications triggered by the tariff hike, according to media reports.&nbsp;
Trending: How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.
Retailers are also feeling the strain. On April 19, Marc Bowker, owner of Alter Ego Comics in Lima, Ohio, told <a href="https://www.businessinsider.com/main-street-trump-trade-war-tariffs-small-businesses-impact-2025-4">Business Insider</a> his supplier costs rose as much as 34%. The increase has forced him to raise prices on imported goods and tighten profit margins to stay afloat. "If you see prices go up at your local small business, it&#8217;s not because we want to,&#8221; he said . "It&#8217;s because we&#8217;re forced to."
Across the board, many small business owners are putting plans on hold according to data from the <a href="https://www.uschamber.com/small-business/small-business-weekly-forecast">U.S. Chamber of Commerce</a>. 12% of small business owners believe it&#8217;s a good time to expand, reflecting a five-point decline from January. Moreover, 19% are planning capital purchases in the next three months, down one point from January.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a>
Cuban encouraged consumers to stock up on essential household goods like soap, toothpaste, and medications, warning that tariffs would eventually drive up shelf prices nationwide.
Meanwhile, industry-wide concern is growing. A survey conducted by <a href="https://www.fictiv.com/ebooks/2025-state-of-manufacturing-report">Fictiv</a> revealed that 77% of manufacturing and supply chain leaders expressed concerns about their ability to manage resources effectively amid trade wars and <a href="https://www.benzinga.com/personal-finance/24/10/41313947/expert-finds-trumps-tax-proposal-drains-money-from-95-of-households-and-funnels-it-to-the-top-5-">tariffs</a>.
In addition, the <a href="https://www.uschina.org/news-releases/new-report-us-china-trade-war-2-0-poised-to-devastate-american-exporters/">U.S.-China Business Council</a> has estimated that some 862,467 American jobs—particularly in agriculture and trade-heavy sectors—could be at risk.
Read Next:
<ul class="wp-block-list">
<li>Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

Personal Finance

TSLA

'Unbelievable People Still Don't Understand Tariffs' – Mark Cuban Highlights Entrepreneur's $30 Million Loss Under Trump's 145% Tariff

Cantor Fitzgerald analyst Kristen Kluska reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Overweight and maintains $30 price target.

CAPR

Cantor Fitzgerald Reiterates Overweight on Capricor Therapeutics, Maintains $30 Price Target

Barclays analyst Michael Leithead maintains Ball (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>) with a Equal-Weight and lowers the price target from $61 to $57.

BALL

Barclays Maintains Equal-Weight on Ball, Lowers Price Target to $57

Mizuho analyst Ann Hynes maintains Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) with a Neutral and lowers the price target from $10 to $8.

FTRE

Mizuho Maintains Neutral on Fortrea Holdings, Lowers Price Target to $8

Etoro Group IPO Price Indicating $61.50 On 621K Shares; IPO Priced At $52/Share On 11,923,018 Shares

<a href="https://www.bloomberg.com/news/articles/2025-05-14/uber-targets-commuters-with-cheaper-pooled-rides-price-lock-pass?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-14/uber-targets-commuters-with-cheaper-pooled-rides-price-lock-pass?embedded-checkout=true</a>

General

UBER

'Uber Targets Commuters With Cheaper Pooled Rides, Price-Lock Pass'- Bloomberg

Barclays analyst Peter Lawson maintains Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) with a Underweight and lowers the price target from $1 to $0.46.

ADAP

Barclays Maintains Underweight on Adaptimmune Therapeutics, Lowers Price Target to $0.46

Mizuho analyst Graig Suvannavejh maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Neutral and lowers the price target from $30 to $20.

APLS

Mizuho Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $20

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 10 years by 5.49% on an annualized basis producing an average annual return of 16.17%. Currently, Chemed has a market capitalization of $8.36 billion. 
Buying $1000 In CHE: If an investor had bought $1000 of CHE stock 10 years ago, it would be worth $4,535.11 today based on a price of $571.49 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747233913_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Chemed Stock In The Last 10 Years

Cantor Fitzgerald analyst Timur Ivannikov maintains Pharvaris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHVS#NASDAQ">PHVS</a>) with a Overweight and lowers the price target from $28 to $25.

PHVS

Cantor Fitzgerald Maintains Overweight on Pharvaris, Lowers Price Target to $25

Exelixis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) reported adjusted earnings of 62 cents per share on Tuesday for the first quarter of 2025, compared to 17 cents a year ago, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of 36 cents</a>.
The cancer-focused company reported quarterly sales of $555.45 million, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45390263/exelixis-announces-first-quarter-2025-financial-results-and-provides-corporate-update" rel="noreferrer noopener">consensus of $498.18 million</a>.
Total revenues included net product revenues of&nbsp;$513.3 million, compared to&nbsp;$378.5 million&nbsp;for the comparable period in 2024.
<ul class="wp-block-list">
<li>The increase in net product revenues was primarily due to an increase in sales volume and an increase in average net selling price.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44499265/fda-approves-exelixis-lead-cancer-drug-cabometyx-for-expanded-use-in-neuroendocrine-tumors" rel="noreferrer noopener">FDA Approves Exelixis&#8217; Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors</a>
&#8220;Exelixis delivered outstanding financial performance in the first quarter of 2025, driven by accelerating growth in Cabometyx demand, new patient starts, and revenues,&#8221; said Michael M. Morrissey, president and CEO of Exelixis.
&#8220;The&nbsp;Exelixis&nbsp;commercial team rapidly mobilized for the launch of CABOMETYX in advanced neuroendocrine tumors (NET) within hours of receiving&nbsp;U.S.&nbsp;regulatory approval in late March. We are very pleased with the initial reception and plan to provide further updates to our 2025 financial guidance as we build momentum on the NET launch and gain further clarity on additional revenue opportunities for 2025,&#8221; Morrissey added.
Guidance: &#8220;Based on the strong first quarter dynamics of CABOMETYX, we&#8217;re increasing our 2025 full year financial guidance for net product revenues and total revenues by&nbsp;$100 million,&#8221; Morrissey said.
The company raised fiscal 2025 sales guidance from $2.15 billion—$2.25 billion to $2.25 billion—$2.35 billion, versus the consensus of $2.25 billion.
On Tuesday, Invenra Inc. announced that its collaboration partner, Exelixis, has initiated the dose-escalation stage of the first-in-human Phase 1 study of XB628 in participants with recurrent advanced or <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">metastatic solid tumors</a>.
XB628 is a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (NKG2A), an inhibitory receptor on NK cells, and programmed cell <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45394458/invenra-highlights-exelixis-initiation-of-phase-1-clinical-study-evaluating-xb628-a-first-in-class" rel="noreferrer noopener">death-ligand 1 (PD-L1)</a>.
The molecule was discovered in part through a collaboration between Exelixis and Invenra.
&#8220;Regarding flagship product Cabometyx, we are encouraged by its continued strength in RCC and expect the recent approval in late-line NETs to potentially drive the next leg of growth,&#8221; William Blair analyst Andy T. Hsieh wrote on Wednesday.
&#8220;The NETs market is expected to grow at a 9% compound annual rate to $4.6 billion by 2030. Based on our prior analysis, the total addressable market for Cabometyx in this indication stands at $900 million, thus representing a material expansion opportunity, in our view.&#8221; 
Price Action: At the last check on Wednesday, EXEL stock was up 4.11% at $38.47 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/05/45405716/firstcash-enters-uk-market-with-394-million-acquisition-of-ht-group" target="_blank" rel="noreferrer noopener">FirstCash Enters UK Market With $394 Million Acquisition Of H&amp;T Group</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Health Care

EXEL

Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance

Entertainment

Press Releases

SUPER BOWL LIX ON FOX AND TUBI GENERATES MORE THAN $800 MILLION IN GROSS ADVERTISING REVENUE

Fox Corporation Chief Financial Officer Steve Tomsic to Participate in Upcoming Barclays Communications and Content Symposium

Fox Corporation Executive Chair and Chief Executive Officer Lachlan Murdoch to Participate in Upcoming Morgan Stanley Technology, Media & Telecom Conference

Fox Corporation President and Chief Operating Officer John Nallen to Participate in Upcoming Deutsche Bank's 33rd Annual Media, Internet & Telecom Conference

SiriusXM Announces Appointment of Anjali Sud to Board of Directors

Fox Corporation Executives to Discuss Third Quarter Fiscal 2025 Financial Results Via Webcast

Commodities

Fox Corporation President and Chief Operating Officer John Nallen to Participate in MoffettNathanson's Media, Internet & Communications Conference 2025

Comments

Fox

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL